Methods of removing interference of CD38 monoclonal antibody in blood transfusion compatibility detection and literature review
-
摘要: 目的 回顾有关达雷妥尤单抗干扰输血相容性检测的文献，以及规避潜在问题的方法，并寻求为安全的输血实践提供临床和实验室建议。方法 采用聚凝胺或二硫苏糖醇(DTT)处理红细胞的方法，进行输血相容性检测。结果 聚凝胺或DTT处理后的红细胞用于输血相容性检测，不规则抗体筛查及鉴定结果为阴性，交叉配血试验相合。结论 聚凝胺或DTT处理红细胞的方法可以去除达雷妥尤单抗对输血相容性检测的干扰。Abstract: Objective To review the literatures on Daratumumab interfering the blood transfusion compatibility testing, as well as ways to avoid these potential problems, and seek clinical and laboratory recommendations for the safety of blood transfusion practice.Methods Using the polybrene or dithiothreitol(DTT) to treat red blood cells for blood transfusion compatibility testing.Results Red blood cells treated with polybrene or DTT were used for blood transfusion compatibility testing, results of irregular antibody screening and identification were negative, and cross-matching was compatibility.Conclusion The application of red blood cells treated with polybrene or DTT can remove the interference of Daratumumab in blood transfusion compatibility testing.
-
Key words:
- CD38 /
- monoclonal antibody /
- blood transfusion compatibility test
-
-
表 2 不规则抗体筛查结果
抗体筛查 筛选Ⅰ 筛选Ⅱ 筛选Ⅲ 自身c 对照c 盐水法 0 0 0 0 0 聚凝胺法 0 0 0 0 1+ 柱凝集法 1+s 1+s 1+s 1+s 1+s 
下载: 导出CSV
-
[1] 杜春红, 隋委伽. 达雷妥尤单抗对输血相容性检测的干扰及应对方案[J]. 中华医学杂志, 2021, 101(33): 2645-2648. doi: 10.3760/cma.j.cn112137-20201221-03415
[2] 糜坚青, 蔡晓红, 王少元, 等. CD38单克隆抗体对输血相容性检测干扰及其应对方案的专家共识[J]. 中国输血杂志, 2021, 34(4): 327-334. https://www.cnki.com.cn/Article/CJFDTOTAL-BLOO202104002.htm
[3] van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future[J]. Blood, 2018, 131(1): 13-29. doi: 10.1182/blood-2017-06-740944
[4] 季嘉敏, 赵万红. 多发性骨髓瘤免疫治疗进展[J]. 临床血液学杂志, 2023, 36(9): 680-687. doi: 10.13201/j.issn.1004-2806.2023.09.014
[5] Du CH, Sui WJ, Huang HT, et al. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment[J]. Leuk Res, 2022, 122: 106953. doi: 10.1016/j.leukres.2022.106953
[6] 宋婕, 孔永奎, 王书亚, 等. 去除CD38单抗对输血相容性检测干扰的简便方法的建立[J]. 中国输血杂志, 2021, 34(9): 974-977. https://www.cnki.com.cn/Article/CJFDTOTAL-BLOO202109010.htm
[7] Velliquette RW, Aeschlimann J, Kirkegaard J, et al. Monoclonal anti-CD47 interference in red cell and platelet testing[J]. Transfusion, 2019, 59(2): 730-737. doi: 10.1111/trf.15033
[8] Chami B, Okuda M, Moayeri M, et al. Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping[J]. Transfusion, 2022, 62(11): 2334-2348. doi: 10.1111/trf.17137
[9] Nedumcheril MT, DeSimone RA, Racine-Brzostek SE, et al. Overcoming drug interference in transfusion testing: a spotlight on daratumumab[J]. J Blood Med, 2021, 12: 327-336. doi: 10.2147/JBM.S213510
[10] 张警丹, 李鹏, 李强, 等. 抗CD38单克隆抗体对多发性骨髓瘤患者交叉配血干扰及输血疗效的影响[J]. 临床血液学杂志, 2022, 35(8): 539-542. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ202208001.htm
[11] Li YY, Li CY, Zhang L, et al. Long-term storage protocol of reagent red blood cells treated with 0.01M dithiothreitol(DTT)for pre-transfusion testing of patients receiving anti-CD38 therapy, daratumumab[J]. Hematology, 2023, 28(1): 2186037. doi: 10.1080/16078454.2023.2186037
[12] Feldman A, Duek AM, Mandel-Benado M, et al. Effective neutralization of daratumumab effects on pre-transfusion testing: a method modification[J]. Clin Lab, 2022, 68(9).
[13] Ehrend E, Manns P, Harenkamp S, et al. Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing[J]. Blood, 2021, 138(9): 814-817. doi: 10.1182/blood.2021011396
[14] Feng CC, Chang CW, Lien ZY, et al. Better resolving of anti-CD38 antibody interference with blood compatibility testing by using manual polybrene methodcompared with dithiothreitol-pretreatment indirect antiglobulin test[J]. J Clin Lab Anal, 2023, 37(8): e24891. doi: 10.1002/jcla.24891
[15] Safić Stanić H, Kruhonja Galić Z, Lukić M, et al. Risk of new alloimmunization in patients on anti-CD38 treatment using tube LISS-IAT method[J]. Transfus Apher Sci, 2024, 63(2): 103873. doi: 10.1016/j.transci.2024.103873
[16] Song J, Fu R. Review: Effects of anti-CD38 monoclonal antibodies on red blood cell transfusion and interventions[J]. J Clin Lab Anal, 2021, 35(12): e23832. doi: 10.1002/jcla.23832
[17] Zhou Y, Chen LY, Jiang TS, et al. 2-Mercaptoethanol(2-ME)-based IATs or Polybrene method mitigates the interference of daratumumab on blood compatibility tests[J]. Hematology, 2021, 26(1): 365-370. doi: 10.1080/16078454.2021.1918916
[18] Yadav S, Gundeti S, Bhave A, et al. Role of daratumumab in the frontline management of multiple myeloma: a narrative review[J]. Expert Rev Hematol, 2023, 16(10): 743-760. doi: 10.1080/17474086.2023.2246651
[19] 强新晨, 杨华莹, 邵俊良. 应用二硫苏糖醇消除达雷木单抗对输血相容性检测干扰的探讨[J]. 中国实验诊断学, 2022, 26(3): 400-403. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSZD202203024.htm
[20] 骆宏, 王贞, 廖志坚, 等. 抗-CD38单克隆抗体对输血前检测试验的干扰及其处理措施[J]. 中国输血杂志, 2020, 33(3): 272-275. https://www.cnki.com.cn/Article/CJFDTOTAL-BLOO202003029.htm
[21] 黎裕元, 张玲, 蔡葵, 等. 改良DTT法用于减少达雷妥尤单抗对血清学检测造成的干扰[J]. 中国实验血液学杂志, 2023, 31(5): 1543-1549. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY202305046.htm
-